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The concept of costimulation has changed the way of 
understanding how T cells recognise and respond to 
antigens 1. The current model of T cell activation 
requires two signals: 
Signal 1: It is only an initiation event. It requires T cell 
receptor recognition and binding to antigen presented 
by antigen presenting cells. However this signal alone 
is necessary but not sufficient to induce T cell 
proliferation.   
Signal 2: It is a costimulatory signal. It results from 
binding of one of both molecules of B7 family (CD80 
and CD86) on antigen presenting cells to one of two 
receptors on T lymphocytes (CD28 and cytotoxic T 
lymphocyte antigen CTLA4). 
If both signals are provided, it results in T cell clonal 
expansion and in the induction of effector functions 
such as lymphokine production, T cell proliferation 
and cytokine secretion 2.     
Costimulation is required for a productive immune 
response to occur. The lack of costimulation after 
engagement of T cell receptor by antigen results in a 
state of antigen specific unresponsiveness termed 
anergy. This places the costimulation pathway at a key 
location for controlling immune response. It also gives 
it a potential role in treatment of diseases such 
autoimmune diseases, organ rejection and tumour 
immunity 2.  
The B7 family of costimulatory ligands currently 
has two members, B7-1 (CD80) and B7-2 (CD86). 
Both B7-1 and B7-2 belong to the immunoglobulin 
gene superfamily 3. CD80 is a 55-kDa glycoprotein 
made up of 288 amino acids with transmembrane 
region and a short 19 amino acid cytoplasmic domain4. 
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bronchial allergic inflammation in asthma. The percentage of expression of 
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CD86 is a 70-kDa glycoprotein made up of 329 amino 
acids, a transmembrane region and a longer 
cytoplasmic domain than CD80 containing potential 
phosphorylation sites for protein kinase. This indicates 
that B7-2 may have a signalling function 5. 
This study was done to assess the expression of 
costimulatory molecules CD80 and CD86 on T 
lymphocytes and monocytes of asthmatic children. The 
effect of clinical grading of asthma and intake of 
inhaled steroids on the level of expression of 
costimulatory molecules was assessed. 
                 
METHODS 
This study was conducted on 56 children, 41 males and 
15 females, during the period from February 2002 to 
August 2002. They were divided into two groups: 
Group I: Asthmatics: This included 44 patients (33 
males and 11 females); their ages ranged from 2 to 14 
years with a mean age of 6.50±2.65 years. The mean 
age of onset of asthma was 2.53±1.61 years and the 
mean duration of illness was4.33± 2.42 years. They 
were selected from patients attending the Chest Clinic, 
Children’s Hospital, Ain Shams University for follow 
up. 
The asthmatic children were classified into 2 
subgroups: 
(1) Asthmatics in acute attack: 
 These included 12 children, 9 males and 3 females, 
with a mean age of 7.11±3.1 years and a mean duration 
of illness of 4.6±2.7 years.  
(2) Asthmatics in between attacks: 
They comprised 32 children (24 male and 8 females) 
with a mean age of 6.50±2.71 years and a mean 
duration of illness of 4.09±2.15 years. They were 
further subdivided into the following clinical 
subgroups according to the revised GINA guidelines 
criteria 6: 
Group Ia: Mild persistent asthmatics: 15 children  
(11 males and 4 females) with a mean age of 5.6±2.0 
years and duration of illness of 3.4±2.1 years. 
Group Ib: Moderate persistent asthmatics: 9 
children (6 males and 3 females) with a mean age of 
6.5±1.8 and duration of illness of 4.2±1.5 years. 
Group Ic: Severe persistent asthmatics: 8 children 
(7 males and 1 female) with a mean age of 8.3±3.9 
years and duration of illness of 5.2±2.7 years. 
According to intake of inhaled steroids, asthmatics 
were subdivided into: 
I) Asthmatics on inhaled steroids: These were 20 
children (14 male and 6 females) with a mean age of 
7.8±2.9 years and a mean duration of illness of 
4.9±2.3 years. They were on fluticasone inhalers (50-
125 μg/puff). 
II) Asthmatics not receiving inhaled steroids: They 
comprised 24 children (17 males and 7 females), 
with a mean age of 5.6±2.1 years and mean duration 
of illness of 3.5±1.9 years. 
Group II: Controls 
This group included 12 healthy age and sex-matched 
children for comparison. 
The studied asthmatic children were subjected to: 
A.  Full history taking, laying stress on duration of 
disease, frequency of acute attacks, nocturnal 
symptoms predisposing factors, drug therapy and 
degree of clinical severity. 
B.  Clinical examination including examination of the 
chest. 
C. Laboratory investigations including: 
1. Complete blood count using Coulter (T-540 cell 
counter) with peripheral blood film examination 
stained with Leishman stain especially for 
lymphocytic and monocytic counts. 
2. Estimation of percentage of CD80 and CD86 
expression on T lymphocytes and monocytes. The 
cell surface markers of both CD80 and CD86 were 
assessed by flow cytometry 7,8 on Coulter Epics XL 
flow cytometry (Coulter electronics, Hielaeh FI, 
USA). The surface marker analysis was done on 
whole blood. The erythrocytes were lysed by adding 
3ml NH4CL (0.83% buffered with KHCO3 pH 7.2) 
for 5 minutes at 37° C. The CD80 labeled to FITC 
(Fluorescein Isothiocyanate) and the CD86 labeled to 
PE (Phycoerythrin) (Cymbus Biotechnology LTD, 
Units J and K, Eagle close, Chandlers Ford, Hants, 
S053 4NF, UK). Both parameters were run along 
with negative isotypic controls (Coulter electronics). 
A sample was considered positive for CD80 or CD86 
when >20% of cells showed the marker.  
 
RESULTS 
The results of this study showed that the percentage of 
CD80 (30.6±18.02) and CD86 (22.11±13.47) 
expression on T lymphocytes in asthmatics in acute 
attack were significantly higher than in the control 
group (CD80 12.25± 5.65, CD86 8.63±5.24, p<0.05). 
On monocytes, the percentage of CD80 (81.78±10.99) 
and CD86 (87.33±8.05) expression in asthmatics 
during acute exacerbation were significantly higher 
than in control group (CD80 45.13±17.02, CD86 
50.38± 18.24; p<0.01), (Table 1). 
In the present study, there was a statistically 
significant higher percentage of expression of both 
CD80 and CD86 on monocytes in asthmatics in 
between attacks compared to control (p<0.01), while 
no statistical significant differences as regards 
percentage of expression on T lymphocytes (p>0.05), 
(Table 2 and Fig 1). 
Comparison between asthmatics in acute 
exacerbation and those in-between attacks revealed 
presence of a statistically significant higher percentage 
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of expression of both CD80 (81.78±10.99) and CD86 
(87.33±8.05) on monocytes in acute asthmatic attacks; 
meanwhile no similar relation could be elicited in the 
expression on T lymphocytes during acute attacks 
(30.6±18.02 and 22.11± 13.47 respectively) compared 
to asthmatics in-between attacks (CD80 20.57±19.94, 
CD86 12.09±15.98) (p> 0.01) (Fig 2) 
The results showed a statistically significant 
difference between severe asthmatics and both mild 
and moderate subgroups (p<0.05) as regards 
coexpression lymphocytes in-between attacks. In 
addition, there was no statistical significant difference 
between mild and moderate subgroups as regards 
levels of coexpression on both lymphocytes and 
monocytes (Tables 3 and 4). 
Concerning the effect of inhaled steroids, the study 
revealed lower expression of CD80 (15.12±19.04) and 
CD86 (11.03±13.84) on T lymphocytes in asthmatics 
on inhaled steroids compared to those who were not 
(CD80% 26.76± 19.29, CD86% 25.48±17.09; p<0.05). 
On monocytes, there was significant decrease of 
expression of CD80 (63.60±20.71) and CD86 (65.8± 
28.51) compared to those not receiving steroids (CD80 
77.04±19.24, CD86 75.62±26.09) (p< 0.05)(Fig 3). 
There was no statistical significant correlation 
between percentage of coexpression and the clinical 





Fig. (1): Example of histogram generated from a case showing expression of 
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Fig (2): Comparison between asthmatics in acute attacks and asthmatics 
in-between attacks as regards mean percentage of CD80 and CD86 
expression on T lymphocytes. 
 
 






























Fig (3): Comparison between asthmatics on inhaled steroids and 
asthmatics not on inhaled steroids as regards mean percentage 





Table (1): Statistical comparison between asthmatics in 
acute attacks and controls as regards percentage of 












10BExpression on T Lymphocytes 
2BCD80 (%) 30.6±18.02 12.25±5.65 2.45 <0.05 (S) 
3BCD86  (%) 22.11±13.47 8.63±5.24 2.26 <0.05 (S) 
17BCoexpression 14.82±29 5.63±3.16 0.29 >0.05 
11BExpression on Monocytes 
CD80 (%) 81.78±10.99 45.13±17.02 5.34 <0.001 (HS) 
CD86 (%) 87.33±8.05 50.38±19.50 5 <0.01 (HS) 







Table (2): Statistical comparison between asthmatics in-
between attacks and controls as regards percentage 
expression of CD80 and CD86 on T lymphocytes and 
monocytes. 
 




Mean ± SD 
13BControls 
(n=12) 
Mean ± SD 
t p 
14BExpression on T Lymphocytes 
5BCD80 (%) 20.57±19.94 12.25±5.65 1.15 >0.05 
6BCD86  (%) 12.09±15.98 8.63±5.24 0.6 >0.05 
Coexpression 8.63±15.66 5.63±3.16 0.53 >0.05 
Expression on Monocytes 
7BCD80  (%) 69.07±21.82 45.13±17.02 2.068 <0.01 (HS) 
8BCD86  (%) 65.87±28.32 50.38±19.50 2.19 <0.05 (S) 
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Table (3) Statistical comparison between asthmatic 
subgroups as regards percentage of CD80 and CD86 

































Table (4): Statistical comparison between asthmatic 
subgroups as regards percentage of coexpression of 
































Table (5): Statistical correlation between coexpression of 
CD80 and CD86 on T  lymphocytes and monocytes with 
some clinical some clinical parameters of the studied 
groups. 




 r p r p 
Age of onset  
(years) -0.202 >0.05 0.148 >0.05 
Asthma duration 
(years) 0.196 >0.05 0.149 >0.05 
IgE  
(IU) -0.194 >0.05 -0.327 >0.05 
TLC 








The basic immunologic event in bronchial asthma is 
the shift of allergen reactive CD4 T lymphocytes 
towards a Th2 phenotype with the production of Th2 
cytokines. Th2 cells can support allergen specific IgE 
production and eosinophils recruitment9. Optimal T 
cell activation by antigen presenting cells requires 
costimluatory signals such as interactions of CD80 and 
CD86 or both with CD28on T lymphocytes 10. 
The results of this study showed that, on T 
lymphocytes, the percentage of CD80 (30.6±18.02) 
and CD86 (22.11± 13.47) expression in asthmatics 
during acute attacks were significantly higher than in 
the control group (CD80 12.25± 5.65, CD86 
8.63±5.24), (p <0.05). On monocytes, percentage of 
CD80 (81.78±10.99) and CD86 (87.33±8.05) 
expression in asthmatics in acute exacerbation were 
significantly higher than in control group (CD80 
45.13±17.02, CD86 50.38± 18.24)  (p <0.01). This was 
in agreement with Hofer, et al. 1998 11 who used flow 
cytometry to analyze expression of both CD80 and 
CD86 on T lymphocytes. They found that atopic 
patients with asthma (exposed to allergen) had 
significantly higher level of CD80 and CD86 
expression than atopic patients not exposed to allergen 
or control subjects. Burastero et al12 stated that the 
outcome of antigen recognition in asthmatic children is 
dependant -at least in part- on the complex interactions 
between costimulatory molecules on antigen 
presenting cells (CD80 and CD86) with their ligands 
on T cells. They added that costimulation is also 
involved in determining which effect profile will be 
acquired by T cells Th1 or Th2 phenotype. Colvita et 
al13 and Correno and Collins14 demonstrated that CD80 
or CD86 costimulation appears to be necessary for 
expression of Th2 cytokines in response to allergen in 
atopic asthmatic children. Either or both these 
molecules remain possible targets for intervention in 
asthma.    
In the present study, there was a statistically 
significant higher percentage of expression of both 
CD80 and CD86 on monocytes in asthmatics in-
between attacks compared to control (p<0.01), while 
no statistical significant differences as regards 
percentage of expression on T lymphocytes (p>0.05). 
This may be due to that in chronic asthmatics in-
between attacks, the memory and effector T cells are 
less dependant on costimulatory signals15. Hance16 
compared between antigen-presenting ability of 
isolated macrophages from healthy and atopic children. 
He found that the poor antigen presenting ability of 
cells of healthy children is related to reduced 
expression and/or function of costimulatory molecules 
on their surface. This is considered a protective 
mechanism for inhibition of local T cell activation in 
healthy lung. Bashian et al17 concluded that the 
impaired costimulation of antigen presenting cells in 
normal healthy tissues can lead to tolerance and 
decrease T cell activation 
Also in the present work, percentage of CD80 and 
CD86 expression on T lymphocytes were higher in 
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asthmatics in acute attacks than in asthmatics in-
between attacks  but did not reach statistical 
significance. However, on monocytes, CD80 and 
CD86 in asthmatics in acute exacerbation were 
significantly higher than those in between attacks. This 
result is in agreement with Nakada et al18 who reported 
that the percentage of expression of CD80 and CD86 
on T cells in-between attacks was not altered, while 
their expression on antigen presenting cells as 
monocytes was significantly upregulated in atopic and 
non-atopic asthmatics. 
Costimulatory molecules (CD80 and CD86) are 
expressed in a fashion which depends on type and state 
of activation of cells. Resting monocytes and B cells 
consecutively express CD86 while CD80 is induced 
only upon activation 19. It is still controversial whether 
and to what extent CD80 and CD86 provide 
qualitatively different signals to T lymphocytes, and 
how they affect progression towards Th1 or Th2. The 
results have been contradictory, Keane Myers et al20 
reported a dependence on CD86 in establishment of 
allergic inflammation while Tsuyuki et al21 concluded 
that CD80 was primarily involved in their animal 
model. Nakada et al18 suggested that CD86 induces the 
differentiation of Th2 cells where as CD80 induces 
Th1 differentiation. They noticed that on monocytes, 
CD86 showed more intense induction, peaking at 6 
hours and then gradually declining, which could 
explain the higher level of CD86 expression on 
monocytes compared to CD80 expression in asthmatics 
in this study. This suggests that in early stages of 
immune reactions, antigen presentation by monocytes 
may become more important than that by B cells. 
Nakada et al22 focused on CD80 and CD86 expression 
on allergen specific T lymphocytes derived from 10 
patients with perennial allergic rhinitis and 10 control , 
stimulated by house dust mite antigen. CD86 on T cells 
was upregulated earlier in allergen stimulation, and 
CD80 on T cells was induced later.  
Balbo et al1 studied the expression of CD80 and 
CD86 on alveolar macrophages in BAL fluid and in 
parallel the efficiency of antigen presentation was 
measured in terms of IL-4 and IL-5 production by 
allergen stimulated T cells. They found that in 
asthmatic subjects percent of CD80 but not CD86 on 
alveolar macrophages were increased at base line and 
did not change following allergen challenge; CD86, 
membrane expression was up regulated following 
allergen challenge indicating that CD86 in vivo is up 
regulated in the 24 hour following allergen exposure 
and that this modulation is functionally relevant. 
Inhibition studies were performed to evaluate the 
functional relevance of CD80 or CD86 in relation to 
effector functions on T cells and whether this response 
involved both CD80 and CD86 stimulation or whether 
one accessory molecule predominated over the other. 
Larche et al23 studied 8 atopic asthmatic subjects and 7 
non-atopic control subjects. BAL T lymphocytes were 
isolated from asthmatic subjects and cultured with 
allergen. Allergen-induced proliferation of BAL T 
cells from asthmatic subjects was inhibited by anti-
CD86 antibodies, not anti-CD80  antibodies, reflecting 
the predominant expression of CD86 by both PBMC 
and BAL cells. In contrast to the airway tissue, Jaffar 
et al24 reported  that CD86 appears to be the principal 
costimulatory molecule required for human PBMC 
response to allergens. They added that allergen 
responses in the airway mucosal tissue and PBMC 
differ in the relative contribution of CD80 and CD86 
where both are required by asthmatic airway tissue, 
whereas CD86 is the principal costimulatory molecule 
in peripheral blood. It is possible that both CD80 and 
CD86 are expressed at low levels in the airway tissues 
so either is insufficient to elicit a costimulatory 
response. Another explanation provided by Balbo et al1 
is that complex interactions involving multiple cell 
types, take place in asthmatic tissues, making it 
difficult to prioritize which specific cellular interaction 
is important in asthma. 
In-between attacks, our results showed a 
statistically significant difference between severe 
asthmatics and both mild and moderate subgroups 
(p<0.05) in terms of coexpression on T lymphocytes. 
There was no statistical significant difference between 
mild and moderate subgroups as regards level of 
coexpression on both lymphocytes and monocytes. The 
relation of costimulatory molecules expression to the 
severity of asthma was demonstrated by the study of 
Mark et al25. They demonstrated that blockade of either 
CD80 or CD86 can decrease asthma severity via 
decreasing airway eosinophilia, IgE and AHR. Several 
studies failed to show statistical significant difference 
between mild, moderate and severe clinical asthma, as 
regards pulmonary functions or cytokine levels in BAL 
or induced sputum. This may suggest that patients 
clinically graded to be mild asthmatics could have 
more advanced stage of bronchial inflammation. This 
was supported by the absence of significance 
difference in the level of expression of CD80 and 
CD86 on monocytes in different clinical grades of 
asthma in the current study. 
Concerning the effect of inhaled steroids, our study 
revealed  a statistically significant lower expression of 
CD80 and CD86 on T lymphocytes in asthmatics on 
inhaled steroids compared to those who are not 
(p<0.05). On monocytes, there was a lower significant 
expression of CD80 and, CD86 compared to those not 
on steroids (p< 0.05).  Grindt et al26 studied the 
influence of glucocorticoids on the regulation of 
costimulatory signals. Human monocytes were purified 
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from peripheral blood of healthy volunteers. 
Expression of CD80 and CD86 were detected by 
reverse transcription-polymerase chain reaction and 
flow cytometry in the absence or presence of 
glucocorticoids. Glucocorticoids selectively inhibited 
the expression of CD80 while leaving CD86 
unaffected. The effect occurs at concentrations that are 
reached during therapeutical application of the 
substances in humans. It is mediated via the 
cytoplasmic glucocorticoid receptor. 
This study concluded that enhanced expression of 
costimulatory molecules CD80 and CD86 on antigen 
presenting cells is probably involved in the 
establishment and maintenance of chronic 
inflammation of airways. Further studies are 
recommended to evaluate other costimulatory signals 
necessary for T cell activation which could 
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